Egypt's Foreign Minister holds talks with Lithuania's gov't chancellor    Trump officials rush to Turkey as Moscow advances to fill Syria void from US retreat    No final Brexit deal on Wednesday: BBC political editor    British Council announces its first 'Science Stars' competition in Egypt    Egypt in talks with World Bank over solid waste management loan    Kenya opens $1.5 bln Chinese-built railway linking Rift Valley town and Nairobi    Grand Nile Tower Arts & Cultural Centre launches second round    AUC students win prestigious award at SensUs 2019    UEFA punishes Lazio for fans' racism at Europa League game    Bulgaria detains 4 soccer fans following racist acts in England match    Egypt's coach Hossam El-Badry satisfied with winning start despite technical problems    Lebanon deploys water cannon, helicopters to fight wildfires across country    Debating local councils law    MPs vent their anger at government    Bulgaria boss Balakov apologizes to England over racist chants during Euro 2020 qualifier    Hundreds released    Petrochemicals hurt Qatar, Gulf stocks mostly quiet early on    Macron on course for clash with Merkel over starting membership talks    Making healthcare universal    Scientists find how deadly malaria parasite jumped from gorillas to humans    Sliding inflation    Luxor's new discoveries    IMF's head Georgieva hails Egypt's economic reforms    Egypt's agricultural exports to China rise in 8 months – report    Egypt's PM, US secretary of energy mull cooperation in energy, electricity    Moroccan film Nomades scoops awards in Alexandria Film Festival    British police order a halt to climate change protests in London    U.S. demands Syria ceasefire, imposes sanctions on Turkey over incursion    Toshiba's JV with Egyptian Elaraby opens regional HQ in South Africa    Six authors vie for Booker prize 2019, Atwood in the lead    In Photos: A sneak peek into rehearsals for the Cleopatra ballet world premiere    Sisi, Ethiopia's PM to meet in Moscow to discuss GERD issue    Sisi: army engaged in attrition phase against terrorism in Sinai since 2013    10K fans to attend Egypt's friendly against Botswana in Alexandria: EFA    Sisi, Ethiopia's PM agree to overcome obstacles in Nile dam talks    Farwell to Egyptian comic actor Talaat Zakaria    Court sentences six to death, 41 to lifetime imprisonment violence related case    Trump says he would release Mideast peace plan after Israeli elections    ACWA Power compares 3 bids to supply production units for Luxor power station    What do you know about gold alloying?    NBE announces EGP 2.5m prizes for handball youth teams for their world achievements    Jennifer Lopez evokes Egyptian outrage post her North Coast performance    Al-Sisi honours Egypt's scholars on Science Day    IS claims responsibility for suicide bombing killing 63 in Afghan wedding    Political parties gear up for parliamentary, senate, local elections    Unprecedented Glory: Egypt win Men's U-19 World Handball Championship    12th National Egyptian Theatre Festival fuel up public theatre art scene    Ministry of Environment has a plan for "black clouds season"    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





Ebola “no longer incurable” as Congo trial finds drugs 90% survival rates
Published in Amwal Al Ghad on 14 - 08 - 2019

Scientists are a step closer to being able to cure the deadly Ebola haemorrhagic fever as two experimental drugs showed survival rates of more than 90 percent in a clinical trial in Congo.
Two experimental drugs – an antibody cocktail named REGN-EB3 developed by Regeneron and a monoclonal antibody called mAb114 – will now be offered to all patients infected with the viral disease in an ongoing outbreak in the Democratic Republic of Congo (DRC).
The drugs showed "clearly better" results, according to the U.S. National Institute of Allergy and Infectious Diseases (NIAID), in a trial of four potential treatments being conducted during the second-largest Ebola outbreak in history, now entering its second year in DRC.
The drugs improved survival rates from the disease more than two other treatments being tested – ZMapp, made by Mapp Biopharmaceutical, and Remdesivir, made by Gilead Sciences – and those products will be now dropped, said Anthony Fauci, one of the researchers co-leading the trial.
The agency said 49 percent of the patients on ZMapp and 53 percent on Remdesivir died in the study. In comparison, 29 percent of the patients on REGN-EB3 and 34 percent on mAb114 died.
Jean-Jacques Muyembe, director general of Congo's Institut National de Recherche Biomédicale in DRC, who co-led the trial, said the results meant that "from now on, we will no longer say that Ebola is incurable."
"These advances will help save thousands of lives," he told reporters.
Anthony Fauci, NIAID's director, also said the results were "very good news" for the fight against Ebola.
The agency said that of the patients who were brought into treatment centres with low levels of virus detected in their blood, 94 percent who got REGN-EB3 and 89 percent on mAb114 survived.
In comparison, two-thirds of the patients who got Remdesivir and nearly three-quarters on ZMapp survived.
Ebola has been spreading in eastern Congo since August 2018 in an outbreak that has now killed at least 1,800 people. Efforts to control it have been hampered by militia violence and some local resistance to outside help.
A vast Ebola outbreak in West Africa from 2013 to 2016 became the world's largest ever when it spread through Guinea, Liberia and Sierra Leone and killed more than 11,300 people.
The Congo treatment trial, which began in November last year, is being carried out by an international research group coordinated by the World Health Organization (WHO).
Mike Ryan, head of the WHO's emergencies program, said the trial's positive findings were encouraging but would not be enough on their own to bring the epidemic to an end.
"The news today is fantastic. It gives us a new tool in our toolbox against Ebola, but it will not in itself stop Ebola," he told reporters.
Jeremy Farrar, director of the Wellcome Trust global health charity, also hailed the success of the trial's findings, saying they would "undoubtedly save lives".
"The more we learn about these two treatments … the closer we can get to turning Ebola from a terrifying disease to one that is preventable and treatable," he said in a statement.
"We won't ever get rid of Ebola but we should be able to stop these outbreaks from turning into major national and regional epidemics."
Some 681 patients at four separate treatment centres in Congo have already been enrolled in the Congo treatment clinical trial, Fauci said. The study aims to enrol a total of 725.
The decision to drop two of the trial drugs was based on data from almost 500 patients, he said, which showed that those who got REGN-EB3 or mAb114 "had a greater chance of survival compared to those participants in the other two arms".
The two promising drugs are made from Ebola antibodies – a protein produced by the immune system to defend against infection. Regeneron's product is a cocktail of three Ebola antibodies, while mAb114 is a single antibody developed by scientists at NIAID.
Source: Reuters


Clic here to read the story from its source.